2 recruiting. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 2 |
| Phase 2 | 1 | Recruiting 1 |
Follow Focal Segmental Glomerulosclerosis: new trials by email Literature Review of Focal Segmental Glomerulosclerosis trials Research Report on Focal Segmental Glomerulosclerosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AMPK-activation by Metformin in FSGS: AMP-FSGS Metformin + Standard of Care, Placebo + Standard of Care - Focal Segmental Glomerulosclerosis | Phase 1 / Phase 2 | Recruiting | Yale University | 30 | 2023-12-14 | 2026-02-03 |
| A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects HS-10390 tablet, Placebo tablet - IgA Nephropathy, Focal Segmental Glomerulosclerosis | Phase 1 | Recruiting | Hansoh BioMedical R&D Company | 84 | 2023-05-23 | 2024-10-09 |
Glomerulosclerosis, Focal Segmental (2) · Glomerulonephritis, IGA (1)
Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Glomerulonephritis (2) · Kidney Diseases (2) · Male Urogenital Diseases (2) · Nephritis (2) · Urogenital Diseases (2) · Urologic Diseases (2) · Autoimmune Diseases (1) · Immune System Diseases (1)
Metformin (1) · Standard of Care (1)
Hansoh BioMedical R&D Company (1) · Yale University (1)
China (1) · United States (1)
Cijiang He (1) · Madhav Menon, MD (1)